MIR002 是一种有效且具有口服活性的 DNA polymerase α (POLA1) 和 HDAC 11 双重抑制剂,可诱导 p53 乙酰化、p21 激活、G1/S 细胞周期停滞和细胞凋亡,并显示出显著的体内抗肿瘤活性。
产品编号: MS-O77186 纯度: 99.0% CAS No.: 2217671-64-0 分子式: C27H29NO5 分子量: 447.52
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

MIR002 是一种有效且具有口服活性的 DNA polymerase α (POLA1) 和 HDAC 11 双重抑制剂,可诱导 p53 乙酰化、p21 激活、G1/S 细胞周期停滞和细胞凋亡,并显示出显著的体内抗肿瘤活性。

生物实验数据

生物活性 MIR002 is a potent and orally active dual inhibitor of DNA polymerase α (POLA1) and HDAC 11 that induces p53 acetylation, p21 activation, G1/S cell cycle arrest, and apoptosis, and exhibits significant in vivo antitumor activity.
IC50 & Target HDAC11:6.09 μM
体外研究
(In Vitro)

MIR002 (24 h) shows antiproliferative activity at nanomolar concentrations (IC50s of 0.25, 2.8, 0.6, 0.41 μM in NCI-H460, H460-R9A, A2780, A2780-DX; IC50s of 0.9, 1.2, 0.22, 0.71, 2.1, 0.52, 0.038, 0.18, 0.42, 1.9, 0.64, 1.1 μM in MM432, MM473, MM487, RAMOS, L-428, U-293, Z-138, NB4, THP-1, MDA-MB231, MDA-MB436, U87MG cells, respectively).
MIR002 (0.0001,0.01, 1, 10 μM) shows inhibitory activity on HDAC11 with an IC50 of 6.09 μM.
MIR002 (0.1, 0.25, 0.4 μM, 24 h) shows a dose-dependent p53 acetylation and p21 induction as well as H2AX Phosphorylation. MIR002 (72 h) leads to cell cycle arrest at the G1-S phase.

Cell Proliferation Assay

Cell Line: MM432, MM473, MM487, RAMOS, L-428, U-293, Z-138, NB4, THP-1, MDA-MB231, MDA-MB436, U87MG cells
Concentration: 10 scalar concentrations
Incubation Time: 24 h
Result: Showed antiproliferative activity at nanomolar concentrations (IC50s of 0.9, 1.2, 0.22, 0.71, 2.1, 0.52, 0.038, 0.18, 0.42, 1.9, 0.64, 1.1 µM in MM432, MM473, MM487, RAMOS, L-428, U-293, Z-138, NB4, THP-1, MDA-MB231, MDA-MB436, U87MG cells, respectively)

Western Blot Analysis

Cell Line: NCI-H460, MM473, MM487, A2780 cells
Concentration: 0.1, 0.25, 0.4 µM
Incubation Time: 24 h
Result: Showed antiproliferative activity at nanomolar concentrations (IC50s of 0.9, 1.2, Showed a dosedependent p53 acetylation and p21 induction as well as H2AX Phosphorylation.

Cell Cycle Analysis

Cell Line: NCI-H460, A2780, MM473, H460-R9A cells
Concentration: 0.25 µM for NCI-H460, 0.6 µM for A2780, 1.2 µM for MM473, 2.8 µM for H460-R9A
Incubation Time: 72 h
Result: Cells were arrested at the G1-S phase.
体内研究
(In Vivo)

MIR002 (50 mg/kg; p.o.; twice a day for 5 days a week, 3 weeks) shows a good tolerability and antitumor activity (TGI=61%).
MIR002 (50 mg/kg; p.o.; twice a day for 5 days a week, 6 weeks) shows an additive antitumor effect with complete disappearance of tumor masses in two animals at the end of the treatment when combination with cisplatin.
MIR002 ( 50 mg/kg, twice a day for 5 days) induces a significant increase of a interferon at its pharmacological active dose (50 mg/kg).

Animal Model: Model: 4-6 weeks old female CD-1 nude mice (NSCLC NCI-H460 model)
Dosage: 50 mg/kg
Administration: p.o.; twice a day for 5 days a week, 3 weeks
Result: Showed a good tolerability and antitumor activity (TGI=61%).
Animal Model: 4-6 weeks old female CD-1 nude mice ( MM473-luc and MM487-Luc)
Dosage: 50 mg/kg combibnated with cisplatin (i.p.; 5 mg/kg; twice a day for 7 days a week, 6 weeks)
Administration: p.o.; twice a day for 5 days a week, 6 weeks
Result: Showed an additive antitumor effect with complete disappearance of tumor masses in two animals at the end of the treatment when combination with cisplatin.
Animal Model: 4-6 weeks old female CD-1 nude mice (Melanoma B16 model)
Dosage: 50 mg/kg
Administration: p.o.; twice a day for 5 days
Result: Induced a significant increase of α interferon at its pharmacological active dose (50 mg/kg).
性状 固体
颜色 White to off-white

化学信息

分子量 447.52
分子式 C27H29NO5
CAS No. 2217671-64-0

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (223.45 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.2345 mL11.1727 mL22.3454 mL55.8634 mL
5 mM0.4469 mL2.2345 mL4.4691 mL11.1727 mL
10 mM0.2235 mL1.1173 mL2.2345 mL5.5863 mL
15 mM0.1490 mL0.7448 mL1.4897 mL3.7242 mL
20 mM0.1117 mL0.5586 mL1.1173 mL2.7932 mL
25 mM0.0894 mL0.4469 mL0.8938 mL2.2345 mL
30 mM0.0745 mL0.3724 mL0.7448 mL1.8621 mL
40 mM0.0559 mL0.2793 mL0.5586 mL1.3966 mL
50 mM0.0447 mL0.2235 mL0.4469 mL1.1173 mL
60 mM0.0372 mL0.1862 mL0.3724 mL0.9311 mL
80 mM0.0279 mL0.1397 mL0.2793 mL0.6983 mL
100 mM0.0223 mL0.1117 mL0.2235 mL0.5586 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础